Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 6;10(19):6341-6348.
doi: 10.12998/wjcc.v10.i19.6341.

Review of clinical characteristics, immune responses and regulatory mechanisms of hepatitis E-associated liver failure

Chong Chen  1 , Shu-Ye Zhang  2 , Liang Chen  3
Affiliations
Review

Review of clinical characteristics, immune responses and regulatory mechanisms of hepatitis E-associated liver failure

Chong Chen et al. World J Clin Cases. .

Abstract

Hepatitis E virus (HEV) is the most common cause of acute liver failure (LF) and one of the most common factors causing acute injury in acute-on-chronic LF (ACLF). When HEV-related LF occurs, a series of changes take place in both the intrahepatic environment and extrahepatic microenvironment. The changed types and distribution of immune cells (infiltrating macrophages and increased lymphocytes) in liver tissue, as well the increased proinflammatory cytokines and chemokines in the blood, indicate that the occurrence and progression of HEV-related LF are closely related to immune imbalance. The clinical features and immune reaction in the body during HEV-related acute LF (ALF) and ACLF are complicated. This review highlights recent progress in elucidating the clinical manifestations of HEV-associated ALF and ACLF and discusses the corresponding systemic immune changes and possible regulatory mechanisms.

Keywords: Acute liver failure; Acute-on-chronic liver failure; Cytokines; Hepatitis E virus; Immune cells; Mechanism.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors declare no conflict of interest related to the manuscript.

Figures

Figure 1
Figure 1
Disease manifestations in hepatitis E virus-associated acute liver failure and acute-on-chronic liver failure. ALF: Acute liver failure; ACLF: Acute-on-chronic liver failure; CLDs: Chronic liver diseases; HIV: Human immunodeficiency virus.
Figure 2
Figure 2
The immunological mechanisms of hepatitis E virus-associated liver failure. IL: Interleukin; IFN: Interferon; TNF: Tumor necrosis factor; TGF-: Transforming growth factor-β; NK: Natural killer; PBMC: Peripheral blood mononuclear cell.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Patterson J, Hussey HS, Silal S, Goddard L, Setshedi M, Spearman W, Hussey GD, Kagina BM, Muloiwa R. Systematic review of the global epidemiology of viral-induced acute liver failure. BMJ Open. 2020;10:e037473. - PMC - PubMed
    1. Patterson J, Hussey HS, Abdullahi LH, Silal S, Goddard L, Setshedi M, Spearman W, Hussey GD, Kagina B, Muloiwa R. The global epidemiology of viral-induced acute liver failure: a systematic review protocol. BMJ Open. 2019;9:e029819. - PMC - PubMed
    1. Koch A, Trautwein C, Tacke F. [Acute liver failure] Med Klin Intensivmed Notfmed. 2017;112:371–381. - PMC - PubMed
    1. Horvatits T, Schulze Zur Wiesch J, Lütgehetmann M, Lohse AW, Pischke S. The Clinical Perspective on Hepatitis E. Viruses. 2019;11 - PMC - PubMed
    1. Zhang S, Chen C, Peng J, Li X, Zhang D, Yan J, Zhang Y, Lu C, Xun J, Li W, Ling Y, Huang Y, Chen L. Investigation of underlying comorbidities as risk factors for symptomatic human hepatitis E virus infection. Aliment Pharmacol Ther. 2017;45:701–713. - PubMed